Instil Bio Halts AXN-2510 Trial, Posts $10.70 Loss Per Share, Holds $76.3M Cash
Instil Bio posted a Q4 net loss per share of $1.21 and a 2025 net loss per share of $10.70. It ended 2025 with $76.3 million in cash and securities, funding operations through 2027, and has halted AXN-2510 trials to prioritize acquisitions and in-licensing.
1. Strategic Refocus on External Innovation
In January 2026, subsidiary Axion Bio discontinued development of AXN-2510 and terminated its license agreement for AXN-2510 and AXN-27M, marking a strategic shift to external innovation through potential acquisitions and in-licensing across multiple therapeutic areas.
2. Fourth Quarter and Full Year Financial Results
In Q4 2025, GAAP R&D expenses rose to $3.5 million from $1.1 million year-over-year while G&A expenses declined to $6.1 million from $10.4 million; GAAP net loss per share was $1.21 for Q4 and $10.70 for full year 2025, compared with $1.82 and $11.39 in 2024.
3. Cash Position and Runway
As of December 31, 2025, Instil maintained $6.6 million in cash and cash equivalents, $0.2 million in restricted cash, and $69.5 million in marketable securities, totaling $76.3 million, which is expected to fund its operating plan beyond 2027.
4. Outlook for Acquisitions and In-Licensing
The company emphasizes disciplined capital deployment and does not intend to provide further updates until a specific acquisition or in-licensing transaction is approved or deemed appropriate for disclosure.